Cartesian Therapeutics (RNAC) Receivables - Net (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Receivables - Net data on file, last reported at $261000.0 in Q1 2026.

• On a quarterly basis, Receivables - Net fell 85.21% year-over-year to $261000.0 in Q1 2026; TTM through Mar 2026 was $261000.0, a 85.21% decrease from a year earlier, with the FY2025 full-year figure at $1.1 million, up 27.87% from the prior year.
• Receivables - Net for Q1 2026 stood at $261000.0, down from $1.1 million in the prior quarter.
• Over the last five years, Receivables - Net for RNAC reached as high as $32.0 million in Q2 2024 and fell as low as $261000.0 in Q1 2026.
• Historically, Receivables - Net has averaged $6.6 million across 5 years, with a median of $4.9 million in 2023.
• Across the five-year window, Receivables - Net surged 494.97% in 2024 and sank 98.9% in 2025, its largest moves.
• Year by year, Receivables - Net stood at $6.6 million in 2022, then decreased by 11.01% to $5.9 million in 2023, then tumbled by 85.14% to $872000.0 in 2024, then gained by 27.87% to $1.1 million in 2025, then plunged by 76.59% to $261000.0 in 2026.
• Per Business Quant data, the three most recent Receivables - Net figures were $261000.0 in Q1 2026, $1.1 million in Q4 2025, and $722000.0 in Q3 2025.